ArticleWorld journal of cardiology2020
Mortality and morbidity in patients with atrial fibrillation and liver cirrhosis.
Article in World journal of cardiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Log-transformed systemic inflammation response index improves prediction of 28-day ICU mortality in critically ill patients with cirrhosis and atrial fibrillation: development in MIMIC-IV and external validation in eICU-CRD.BMC gastroenterology · 2026Article
- Managing Coagulation Abnormalities, Bleeding, and Thrombosis in Patients with Cirrhosis.Journal of general internal medicine · 2026Review
- Trends in atrial fibrillation/atrial flutter and cirrhosis-related mortality in the United States from 1999 to 2020: a CDC WONDER analysis.Annals of medicine and surgery (2012) · 2026Review
- Circulating biomarkers and mortality in atrial fibrillation: the REasons for Geographic And Racial Differences in Stroke study.European heart journal open · 2026Article
- When Atrial Fibrillation Meets Alcoholic Liver Cirrhosis: Can Direct Oral Anticoagulants Bridge the Therapeutic Gap?Biomedicines · 2026Review
- Paroxysmal Atrial Fibrillation in Liver Diseases: Epidemiology and Possible Pathophysiological Mechanisms.Journal of clinical medicine · 2026Article
- Assessment of the efficiency and safety of anti-coagulation therapy in patients with liver cirrhosis and atrial fibrillation.Clinical and experimental hepatology · 2023Article
- Role of Galectin in Cardiovascular Conditions including Cirrhotic Cardiomyopathy.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Dysregulated Calcium Handling in Cirrhotic Cardiomyopathy.Biomedicines · 2023Review
- Anticoagulation in Patients with Liver Cirrhosis: Friend or Foe?Digestive diseases and sciences · 2023Review
- Anticoagulation for Atrial Fibrillation in Patients with Decompensated Liver Cirrhosis: Bold and Brave?Diagnostics (Basel, Switzerland) · 2023Review
- Cardiac risk stratification of the liver transplant candidate: A comprehensive review.World journal of transplantation · 2022Review
- Atrial fibrillation increases inpatient and 4-year all-cause mortality in critically ill patients with liver cirrhosis.Annals of translational medicine · 2021Article
- Risk Factors of Atrial Arrhythmia in Patients With Liver Cirrhosis: A Retrospective Study.Frontiers in cardiovascular medicine · 2021Article
- Anticoagulation in patients with atrial fibrillation and liver cirrhosis.Annals of gastroenterologyReview
- Assessing Safety of Anticoagulation for Atrial Fibrillation in Patients with Cirrhosis: A Real-World Outcomes Study.Journal of cardiovascular pharmacology and therapeuticsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAtrial fibrillation (AF) is the most common cardiac arrhythmia encountered in clinical practice. However, the outcomes associated with AF in hospitalized patients with liver cirrhosis are unknown.
aimTo determine the outcomes of hospitalized patients with liver cirrhosis and AF.
methodsIn this study, we examined morbidity and mortality of patients with concomitant AF and liver cirrhosis from the National Inpatient Sample database, the largest publicly available inpatient healthcare database in the United States.
resultsA total of 696937 patients with liver cirrhosis were included, 45745 of whom had concomitant AF (6.6%). Liver cirrhosis patients with AF had higher rates of in-hospital mortality (12.6%
conclusionIn subjects with liver cirrhosis, AF is associated with higher rates of inpatient mortality, stroke, and acute kidney injury compared to those who do not have the cardiac arrhythmia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.